MBL (mL per cycle) · women with heavy menstrual bleeding
1 finding from 1 review
Number of days' bleeding · women with heavy menstrual bleeding
1 finding from 1 review
Quality of life · women with heavy menstrual bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
MBL (mL per cycle) · women with heavy menstrual bleeding
1 finding from 1 review
Quality of life · women with heavy menstrual bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Days of bleeding · women with heavy menstrual bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete remission · idiopathic steroid‐resistant nephrotic syndrome in children
IV showed no clear difference in complete remission compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Partial remission ( · idiopathic steroid‐resistant nephrotic syndrome in children
IV showed no clear difference in partial remission compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Remission · idiopathic steroid‐resistant nephrotic syndrome in children
IV showed no clear difference in continuing remission at one year compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Adverse events: renal insufficiency · idiopathic steroid‐resistant nephrotic syndrome in children
IV showed no clear difference in adverse events: renal insufficiency compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Adverse effects ‐ Bacterial infection clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether IV changes adverse events: bacterial infection compared with oral cyclophosphamide (very low certainty).
1 finding from 1 review
Adverse events: Vomiting · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether IV changes adverse events: vomiting compared with oral cyclophosphamide (very low certainty).
1 finding from 1 review
Alopecia · idiopathic steroid‐resistant nephrotic syndrome in children
IV showed no clear difference in adverse events: alopecia compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Complete remission (no further aphthous episodes to 6 months) · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 6 months: complete remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Treatment response at 6 months: partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 6 months: partial remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Complete or partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 6 months: complete or partial remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Treatment response at 18 months ‐ Sustained remission/steroid sensitive relapses Clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 18 months: sustained… compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Treatment response at 18 months ‐ CKD clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 18 months: CKD compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Adverse events: hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide may leads to lower adverse events: hypertension compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Adverse effects ‐ Bacterial infection clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in adverse events: bacterial infections compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review